Study guide

5.2 Heart Failure & Cardiomyopathies

USMLE Step 3 Exam

Track your progress as you read

Finished sections get a check mark.

1 Foundations - Biostatistics & Study Design

1.1 Study Designs & Clinical Trials 1.2 Hypothesis Testing & Statistical Significance 1.3 Measures of Association & Diagnostic Accuracy

2 Foundations - Epidemiology & Literature Interpretation

Section 2.1: Epidemiology & Risk Measures Section 2.2: Interpretation of Medical Literature & Ads Section 2.3: Preventive Medicine & Screening Guidelines

3 Foundations - Ethics & Communication

3.1 Medical Ethics & Patient Autonomy 3.2 Professionalism & Communication Skills 3.3 Legal Medicine & Informed Consent

4 Foundations - Patient Safety & Systems

Section 4.1: Patient Safety & Error Reduction Section 4.2: Quality Improvement & Systems-Based Practice Section 4.3: Healthcare Delivery Systems & Transitions of Care

5 Cardiovascular Management

5.1 Ischemic Heart Disease & Myocardial Infarction 5.2 Heart Failure & Cardiomyopathies 5.3 Arrhythmias & Conduction System Disorders 5.4 Vascular Diseases & Hypertension Management

6 Respiratory Management

Section 6.1: Obstructive Lung Diseases Section 6.2: Restrictive & Interstitial Lung Diseases Section 6.3: Infectious Pulmonary Diseases Section 6.4: Pulmonary Vascular & Pleural Diseases

7 Gastrointestinal & Hepatic Management

Esophageal & Gastric Disorders Intestinal & Colorectal Disorders Hepatic, Biliary, & Pancreatic Diseases Nutritional & Malabsorptive Syndromes

8 Renal, Urinary, & Endocrine Management

Section 8.1: Acute Kidney Injury & Chronic Kidney Disease Section 8.2: Fluid, Electrolyte, & Acid-Base Disorders Section 8.3: Diabetes Mellitus & Metabolic Syndrome Section 8.4: Thyroid, Adrenal, & Pituitary Disorders

9 Neurology, Special Senses, & Behavioral Health

9.1 Cerebrovascular Disease & Stroke 9.2 Neurodegenerative & Demyelinating Disorders 9.3 Psychiatric Emergencies & Substance Use Disorders 9.4 Common Mood, Anxiety, & Psychotic Disorders

10 Obstetrics & Gynecology

10.1 Antepartum Care & Pregnancy Complications 10.2 Intrapartum Management & Postpartum Care 10.3 Gynecology & Breast Disorders

11 Pediatrics, Human Development, & Multisystem Care

11.1 Normal Development & Childhood Immunizations 11.2 Common Pediatric & Neonatal Illnesses 11.3 Multisystem & Rheumatologic Diseases

12 Skin, Musculoskeletal, & CCS Case Management

Section 12.1: Common Dermatologic Presentations Section 12.2: Acute & Chronic Musculoskeletal Injuries Section 12.3: Computer-Based Case Simulations (CCS) Strategy

5.2 Heart Failure & Cardiomyopathies

Key Takeaways Explain This Topic AI

Foundational guideline-directed medical therapy (GDMT) for HFrEF consists of an ARNI (sacubitril/valsartan), a beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), an MRA (spironolactone or eplerenone), and an SGLT2 inhibitor.

Acute decompensated heart failure is managed based on perfusion and congestion profiles; volume overload (wet) requires IV loop diuretics, while cardiogenic shock (cold and wet) necessitates IV inotropes like dobutamine.

Hypertrophic cardiomyopathy features asymmetric septal hypertrophy and LVOT obstruction; first-line therapy is beta-blockers or verapamil, while vasodilators, high-dose diuretics, and inotropes are contraindicated.

Last updated: July 2026

Heart Failure & Cardiomyopathies

Step 3 Clinical Focus: The management of heart failure (HF) requires understanding the distinction between systolic and diastolic dysfunction, the classification and management of acute decompensated heart failure (ADHF), and the systematic implementation of guideline-directed medical therapy (GDMT). Additionally, differentiating hypertrophic, dilated, and restrictive cardiomyopathies is a major exam focus.

Systolic vs. Diastolic Dysfunction

Heart failure is clinically categorized by left ventricular ejection fraction (LVEF). Heart Failure with reduced Ejection Fraction (HFrEF, LVEF ≤ 40%) is primarily characterized by impaired myocardial contractility (systolic dysfunction), leading to eccentric hypertrophy and ventricular dilatation. Common causes include ischemic heart disease, dilated cardiomyopathy, and chronic hypertension. Heart Failure with preserved Ejection Fraction (HFpEF, LVEF ≥ 50%) is characterized by impaired myocardial relaxation and increased ventricular stiffness during diastole (diastolic dysfunction), leading to elevated filling pressures despite normal cavity size. Common etiologies include aging, long-standing hypertension, obesity, and amyloidosis. Both conditions present with dyspnea, orthopnea, paroxysmal nocturnal dyspnea, and peripheral edema. Initial diagnostic workup includes a B-type natriuretic peptide (BNP) level to rule out non-cardiac causes of dyspnea, followed by a transthoracic echocardiogram to assess ejection fraction, chamber sizes, and valvular function.

Acute Decompensated Heart Failure (ADHF)

ADHF represents a sudden worsening of heart failure symptoms, requiring prompt assessment and classification based on hemodynamic profiles: perfusion (warm vs. cold) and congestion (dry vs. wet). Most patients present as "warm and wet" (adequate perfusion, signs of volume overload). Initial management focuses on aggressive intravenous loop diuretics (e.g., furosemide) using double the patient's home oral daily dose. If the patient is hypertensive, IV vasodilators (such as nitroglycerin or nitroprusside) are added to reduce preload and afterload. For patients who are "cold and wet" (impaired perfusion and fluid overload, signaling cardiogenic shock), intravenous inotropic support with agents like dobutamine (a beta-1 agonist) or milrinone (a phosphodiesterase-3 inhibitor) is indicated to improve cardiac output. In these patients, vasodilators must be avoided if hypotension is present. Non-invasive positive pressure ventilation should be initiated for acute pulmonary edema with respiratory distress to reduce preload. Serum electrolytes, renal function, and cardiac enzymes must be monitored closely during aggressive diuresis, as rapid fluid removal can precipitate acute kidney injury.

Guideline-Directed Medical Therapy (GDMT) for HFrEF

The modern therapeutic framework for HFrEF is built upon four foundational pharmacological pillars, initiated and uptitrated to target doses as tolerated:

Angiotensin Receptor-Neprilysin Inhibitor (ARNI): Sacubitril/valsartan is preferred over ACE inhibitors or ARBs as first-line therapy to reduce hospitalization and mortality. If switching from an ACE inhibitor to an ARNI, a 36-hour washout period is mandatory to prevent life-threatening angioedema.

Beta-blockers: Specifically carvedilol, metoprolol succinate, or bisoprolol. These must be initiated only when the patient is stable and euvolemic, as starting them during acute decompensation can worsen heart failure.

Mineralocorticoid Receptor Antagonists (MRAs): Spironolactone or eplerenone, indicated for patients with NYHA class II-IV symptoms and LVEF ≤ 35%, provided renal function is adequate (creatinine < 2.5 mg/dL in men) and potassium is monitored (< 5.0 mEq/L).

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Empagliflozin or dapagliflozin, which reduce cardiovascular mortality and heart failure hospitalizations regardless of diabetes status.

Secondary therapies include loop diuretics for volume control, hydralazine/isosorbide dinitrate for Black patients with persistent NYHA class III-IV symptoms despite optimal GDMT, and ivabradine for patients in sinus rhythm with a resting heart rate ≥ 70 beats per minute on maximally tolerated beta-blockers. Device therapies, including implantable cardioverter-defibrillators (ICDs) for primary prevention of sudden cardiac death and cardiac resynchronization therapy (CRT) for patients with LVEF ≤ 35%, sinus rhythm, and LBBB with QRS duration ≥ 150 ms, are evaluated after at least 3 months of optimal GDMT.

Cardiomyopathies

Hypertrophic Cardiomyopathy (HCM): An autosomal dominant condition caused by mutations in sarcomeric proteins (e.g., beta-myosin heavy chain). It features asymmetric septal hypertrophy, leading to left ventricular outflow tract (LVOT) obstruction due to systolic anterior motion (SAM) of the mitral valve. Physical exam reveals a harsh systolic crescendo-decrescendo murmur at the left sternal border that increases with maneuvers that decrease preload (Valsalva, standing) and decreases with maneuvers that increase preload or afterload (squatting, handgrip). This dynamic change distinguishes it from aortic stenosis, which increases with squatting and decreases with Valsalva. First-line medical therapy consists of beta-blockers or non-dihydropyridine calcium channel blockers (verapamil) to prolong diastole and increase LV filling. Avoid vasodilators, high-dose diuretics, and inotropes, which worsen obstruction. Surgical myectomy or mavacamten are indicated for refractory symptoms.

Dilated Cardiomyopathy (DCM): Characterized by left ventricular enlargement and systolic dysfunction. Etiologies include genetic mutations (e.g., titin gene), viral myocarditis (coxsackievirus B), toxic exposures (alcohol, cocaine, doxorubicin), peripartum state, and Chagas disease. Differentiating doxorubicin cardiotoxicity (myocyte necrosis, irreversible) from trastuzumab-induced cardiotoxicity (myocardial dysfunction, reversible) is highly relevant for oncology patients. Treatment follows standard HFrEF GDMT, alongside abstinence from toxins and management of the underlying cause.

Restrictive Cardiomyopathy (RCM): Characterized by normal or decreased diastolic volume of one or both ventricles with normal wall thickness, but severely impaired ventricular filling. Causes include systemic amyloidosis (either light chain AL or transthyretin ATTR), sarcoidosis, hemochromatosis, and radiation therapy. Diagnosis is supported by low voltage on ECG despite thickened ventricular walls on echocardiogram (classically a speckled appearance), cardiac MRI, or endomyocardial biopsy. Treatment involves careful volume management with diuretics, alongside disease-specific therapies (e.g., tafamidis for ATTR amyloidosis).